Document 0817
 DOCN  M9590817
 TI    Rapid changes in human immunodeficiency virus type 1 RNA load and
       appearance of drug-resistant virus populations in persons treated with
       lamivudine (3TC).
 DT    9509
 AU    Schuurman R; Nijhuis M; van Leeuwen R; Schipper P; de Jong D; Collis P;
       Danner SA; Mulder J; Loveday C; Christopherson C; et al; Antiviral
       Therapy Laboratory (Department of Virology), University; of Amsterdam,
       Academic Medical Centre, Netherlands.
 SO    J Infect Dis. 1995 Jun;171(6):1411-9. Unique Identifier : AIDSLINE
       MED/95287030
 AB    The effect of the appearance of drug-resistant human immunodeficiency
       virus type 1 (HIV-1) on viral RNA load was studied in patients treated
       with the reverse transcriptase inhibitor lamivudine. During the first 12
       weeks of treatment, HIV-1 RNA concentrations and amino acid changes in
       codon 184, causing high-level resistance to lamivudine, were determined
       in longitudinal serum samples from HIV-1 p24 antigen-positive and
       negative patients. A marked decline in the amount of HIV-1 RNA
       (approximately 95% below baseline) and HIV-1 p24 antigen was observed
       within 2 weeks, followed by a rise that coincided with the appearance of
       lamivudine-resistant viruses in serum (isoleucine mutants initially,
       which were subsequently replaced by valine variants). After 12 weeks, a
       partial antiviral effect was observed despite the presence of a complete
       codon 184 mutant virus population in serum. This study shows that the
       rapid appearance of drug-resistant virus in serum is followed by an
       increase in viral RNA load.
 DE    CD4 Lymphocyte Count  Drug Resistance, Microbial  Human  HIV Core
       Protein p24/ANALYSIS  HIV Infections/*DRUG THERAPY/MICROBIOLOGY
       HIV-1/*GENETICS  Longitudinal Studies  Male  Reverse
       Transcriptase/ANTAGONISTS & INHIB  RNA, Viral/*METABOLISM  Support,
       Non-U.S. Gov't  Zalcitabine/*ANALOGS & DERIVATIVES/THERAPEUTIC USE
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).